Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Paraherquamide A

Cholinergic antagonist
 
ALX-380-215-M001 1 mg 347.00 USD
Do you need bulk/larger quantities?
 
Antibiotic. Selective and competitive cholinergic antagonist that distinguishes subtypes of cholinergic receptors. Anti-helmintic.

Product Specification

Alternative Name:VM 29919
 
Formula:C28H35N3O5
 
MW:493.6
 
Source:Isolated from Penicillium simplicissimum MST-FP116A.
 
CAS:77392-58-6
 
RTECS:RV0545000
 
Purity:≥95% (HPLC)
 
Appearance:White to off-white powder.
 
Solubility:Soluble in 100% ethanol, methanol, dimethyl formamide or DMSO.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
380-215
Please mouse over
380-215

Product Literature References

Evaluation of broad-spectrum anthelmintic activity in a novel assay against Haemonchus contortus, Trichostrongylus colubriformis and T. sigmodontis in the gerbil Meriones unguiculatus: D.A. Ostlind, et al.; J. Helminthol. 80, 393 (2006), Abstract;
Anthelmintic paraherquamides are cholinergic antagonists in gastrointestinal nematodes and mammals: E.W. Zinser, et al.; J. Vet. Pharmacol. Ther. 25, 241 (2002), Abstract;
Paraherquamide and 2-deoxy-paraherquamide distinguish cholinergic receptor subtypes in Ascaris muscle: A.P. Robertson, et al.; J. Pharmacol. Exp. Ther. 302, 853 (2002), Abstract; Full Text
Acute toxicity of paraherquamide and its potential as an anthelmintic: W.L. Shoop, et al.; Am. J. Vet. Res. 53, 2032 (1992), Abstract;
Novel antinematodal and antiparasitic agents from Penicillium charlesii. I. Fermentation, isolation and biological activity: J.G. Ondeyka, et al.; J. Antibiot. (Tokyo) 43, 1375 (1990), Abstract;

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,